127 related articles for article (PubMed ID: 12163847)
1. Endocrine dismodulation and cancer.
Portier CJ
Neuro Endocrinol Lett; 2002 Jul; 23 Suppl 2():43-7. PubMed ID: 12163847
[TBL] [Abstract][Full Text] [Related]
2. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
[TBL] [Abstract][Full Text] [Related]
3. Energy balance, physical activity, and cancer risk.
Fair AM; Montgomery K
Methods Mol Biol; 2009; 472():57-88. PubMed ID: 19107429
[TBL] [Abstract][Full Text] [Related]
4. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
5. The pill and the breast.
Drife JO
IPPF Med Bull; 1984 Dec; 18(6):1-2. PubMed ID: 12313402
[TBL] [Abstract][Full Text] [Related]
6. Environmental and chemical carcinogenesis.
Wogan GN; Hecht SS; Felton JS; Conney AH; Loeb LA
Semin Cancer Biol; 2004 Dec; 14(6):473-86. PubMed ID: 15489140
[TBL] [Abstract][Full Text] [Related]
7. [Receptivity to the sex steroids, physiopathological aspects].
Bercovici JP
Contracept Fertil Sex (Paris); 1984 Jun; 12(6):821-7. PubMed ID: 12313177
[TBL] [Abstract][Full Text] [Related]
8. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario.
Carruba G
J Cell Biochem; 2007 Nov; 102(4):899-911. PubMed ID: 17786930
[TBL] [Abstract][Full Text] [Related]
9. Hormone cross-regulation in the tadpole brain: developmental expression profiles and effect of T3 exposure on thyroid hormone- and estrogen-responsive genes in Rana pipiens.
Hogan NS; Crump KL; Duarte P; Lean DR; Trudeau VL
Gen Comp Endocrinol; 2007; 154(1-3):5-15. PubMed ID: 17400220
[TBL] [Abstract][Full Text] [Related]
10. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of disease: Mutations of G proteins and G-protein-coupled receptors in endocrine diseases.
Lania AG; Mantovani G; Spada A
Nat Clin Pract Endocrinol Metab; 2006 Dec; 2(12):681-93. PubMed ID: 17143315
[TBL] [Abstract][Full Text] [Related]
12. [Phylogeny and evolution of hormone systems].
Feix M; Hoch M
Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Nov; 37(11):651-8. PubMed ID: 12404141
[TBL] [Abstract][Full Text] [Related]
13. Vitamins as hormones.
Reichrath J; Lehmann B; Carlberg C; Varani J; Zouboulis CC
Horm Metab Res; 2007 Feb; 39(2):71-84. PubMed ID: 17326003
[TBL] [Abstract][Full Text] [Related]
14. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.
Platz EA; Giovannucci E
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):237-53. PubMed ID: 15663987
[TBL] [Abstract][Full Text] [Related]
15. Progestins and breast cancer.
Pasqualini JR
Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():32-41. PubMed ID: 17943537
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
17. A treatise on hazards of endocrine disruptors and tool to evaluate them.
Roy P; Pereira BM
Indian J Exp Biol; 2005 Nov; 43(11):975-92. PubMed ID: 16313061
[TBL] [Abstract][Full Text] [Related]
18. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
[TBL] [Abstract][Full Text] [Related]
19. Signaling mechanisms in progesterone-neurotransmitter interactions.
Mani SK
Neuroscience; 2006; 138(3):773-81. PubMed ID: 16310962
[TBL] [Abstract][Full Text] [Related]
20. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
Kim HJ; Cui X; Hilsenbeck SG; Lee AV
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
